Gebelikte Tiroid Fonksiyon Bozukluğunda Kullanılan İlaçlar ve Toksisiteleri

Esra TEL* ve Suna SABUNCUOĞLU *°

* Hacettepe Üniversitesi, Eczacılık Fakültesi, Farmasötik Toksikoloji Anabilim Dalı Sıhhiye, 06100, Ankara, Türkiye

° Corresponding Author;
Tel: + 90 312 305 21 78,
Faks : + 90 312 311 47 77,
E-mail: sunaatasayar@gmail.com

 

Summary

Monoamine oxidases (MAO) having two isoforms (A and B) with different substrate selectivities are flavoproteins which are responsible for the oxidative deamination of endogenous and xenobiotic amines. The first MAO inhibitor compounds were launched as antidepressants in the 1950s. These first generation MAO inhibitors which do not have isoform selectivities and inhibit the enzyme irreversibly have been withdrawn from the market due to serious side effects and drug-food interactions. It was determined that increased activity of monoamine oxidases is responsible for the pathogenesis of neurodegenerative and depressive disorders in the brain and design of reversible and selective inhibitors for MAO-A or MAO-B isoforms has been emphasized in ongoing research.
This review article describes recent developments in various chemical structures (pyrazoline, oxadiazole, coumarin, xanthine, chalcone, etc.) of MAO inhibitors, their structure-activity relationships and their role in neurodegenerative diseases.

Key Words :
MAO-B inhibitors, Alzheimer’s Disease, coumarin, pyrazoline, chalcone, xanthine